Cláudia Murta de Oliveira

Author

Also Known As

Abul Kashem Munir, Claudia M De Oliveira, Claudia Murta de Oliveira, Claudia Murta de Oliveira, Cláudia Murta de Oliveira

Publications

689

Citations

H-Index

Concepts

All Affiliations

Grupo Santa Casa de Belo Horizonte Merck & Co., Inc., Rahway, NJ, USA (United States)Foothills Medical Centre University of Calgary

About

Cláudia Murta de Oliveira is an author at Grupo Santa Casa de Belo Horizonte specializing in infection control, medicine, and antibiotics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	1	1	61
2	Antibiotics	1	1	61
3	Clinical Microbiology	1	1	61
4	Antimicrobial Resistance	1	1	61
5	Infection Control	1	1	61

Cláudia Murta de Oliveira

Publications

585

Citations

H-Index

Page 1

	Year	Citations
RESTORE-IMI 1: A Multicenter, Randomized, Double-blind Trial Comparing Efficacy and Safety of Imipenem/Relebactam vs Colistin Plus Imipenem in Patients With Imipenem-nonsusceptible Bacterial Infections J. Motsch, Cláudia Murta de Oliveira, V.P. Stus, Clinical Infectious Diseases	2019	384
The Adjuvanted Recombinant Zoster Vaccine Confers Long-Term Protection Against Herpes Zoster: Interim Results of an Extension Study of the Pivotal Phase 3 Clinical Trials ZOE-50 and ZOE-70 Céline Boutry, Andrew Hastie, Javier Díez‐Domingo, Clinical Infectious Diseases	2021	90
Cadazolid for the treatment of Clostridium difficile infection: results of two double-blind, placebo-controlled, non-inferiority, randomised phase 3 trials Dale N. Gerding, Oliver A. Cornely, Simon Grill, The Lancet Infectious Diseases AntibioticsClostridium Difficile InfectionAntibiotic AdjuvantRandomised Phase 3Pharmacotherapy	2019	61
A Randomized, Double-Blind, Phase 3 Safety and Efficacy Study of Ridinilazole Versus Vancomycin for Treatment of <i>Clostridioides difficile</i> Infection: Clinical Outcomes With Microbiome and Metabolome Correlates of Response Pablo C. Okhuysen, Mayur Ramesh, Thomas Louie, Clinical Infectious Diseases	2024	28
Double-Blind, Placebo-Controlled Study of Bezlotoxumab in Children Receiving Antibacterial Treatment for <i>Clostridioides difficile</i> Infection (MODIFY III) Thomas J. Sferra, Tomáš Merta, Michael Neely, Journal of the Pediatric Infectious Diseases Society	2023	12
Enpatoran in <scp>COVID</scp>‐19 pneumonia: Safety and efficacy results from a phase <scp>II</scp> randomized trial John E. McKinnon, Joel Santiaguel, Cláudia Murta de Oliveira, Clinical and Translational Science	2023	10

Page 1